New possibilities for MASH treatment: Confirmation of the effectiveness of 2-hydroxybenzylamine
A new study published in the Feb 2025 issue of Nutrients highlights the therapeutic promise of 2-hydroxybenzylamine (2-HOBA) in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The research demonstrates that 2-HOBA effectively scavenges reactive dicarbonyl compounds, leading to reduced hepatic inflammation and fibrosis, and improved liver function.
In this study, MASH model mice were treated with 2-HOBA to evaluate its pharmacological effects. The treatment significantly reduced the expression of hepatic inflammatory and fibrotic markers, indicating an overall improvement in liver health. Notably, 2-HOBA was shown to neutralize toxic dicarbonyl species generated by oxidative stress, thereby preventing liver cell injury.
These findings support the potential of 2-HOBA as a novel therapeutic candidate for MASH. As interest in new treatments for MASH and liver fibrosis grows, non-clinical pharmacology platforms such as the STAM™ model offered by SMC Laboratories are playing an increasingly critical role in advancing preclinical research.